E85
Conditions
Interventions
Group 1: In addition to standardized, subject-specific clinical methods (e.g. general anamnesis, internal/cardiological examination, neurological assessment (NIS), ophthalmological examination), the a
Sponsors
Universitätsmedizin Charité ACCB
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: presence of amyloidosis
Exclusion criteria
Exclusion criteria: lack of consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improving patient care (internal and external quality assurance) through a) Use and documentation of uniform diagnostic and therapeutic standards in a multidisciplinary team specialized in amyloidosis b) Recording of previous diagnostic parameters and evaluation of the time from the onset of symptoms, the first doctor-patient contact to the definitive diagnosis c) Detection of parameters of disease activity d) In the case of monogenetic diseases, screening of asymptomatic carriers and determination of the onset of the disease e) standardized therapy monitoring f) evaluation of survival rate including prognostic factors | — |
Secondary
| Measure | Time frame |
|---|---|
| Collection of epidemiological parameters | — |
Countries
Germany
Contacts
Public ContactKatrin Hahn
Universitätsmedizin Charité
Outcome results
None listed